Is mRNA-1010 the breakthrough Moderna needs beyond COVID-19 vaccines?
Moderna’s mRNA-1010 has cleared a major regulatory hurdle, but evidence in older adults, higher reactogenicity and seasonal contracting could limit its early impact.
Pharma & Biotech
Pharma & Biotech
Can uniQure’s AMT-260 gene therapy become an alternative to epilepsy surgery?
Explore whether uniQure’s AMT-260 gene therapy can rival epilepsy surgery after early seizure reductions in a small first-in-human cohort.
Pharma & Biotech
Memento Medicines launches with $93m, but can MMT-205 challenge retinal drug leaders?
Discover how Memento Medicines plans to challenge retinal drug leaders with $93 million, MMT-205 and a direct Tie2 activation strategy.
Medical Devices & Diagnostics
XEOS AURA 10 improves breast cancer margin detection, but is it ready for routine surgery?
Discover how XEOS AURA 10 could improve breast cancer margin detection while cost, workflow demands and false positives limit wider adoption.
Features & Analysis
Can Sanofi’s CirCLIQ strategy change how anti-CD38 therapies reach patients?
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
Pharma & Biotech
Could Sanofi’s Sarclisa SC approval change how Japan treats multiple myeloma?
Find out how Sanofi’s Sarclisa SC approval in Japan could change multiple myeloma treatment delivery and strengthen its oncology strategy today!
Pharma & Biotech
Why AMT-260’s early epilepsy data could shape the next test for brain-delivered gene therapy
Find out how uniQure’s AMT-260 early epilepsy data could shape the next test for brain-delivered gene therapy.
Pharma & Biotech
Can Kovina Therapeutics turn HPV16 E6 from an undruggable viral protein into a cancer target?
See how Kovina Therapeutics’ HPV16 E6 inhibitors restore p53 in preclinical models and what must happen before human trials.
Medical Devices & Diagnostics
Can earlier Symphony thrombectomy accelerate heart recovery in intermediate-risk pulmonary embolism?
Find out how Imperative Care’s SYMPHONY-PE analysis could reshape thrombectomy timing in intermediate-risk pulmonary embolism.
Medical Devices & Diagnostics
Fujifilm scales New Jersey operations as ELUXEO and therapeutic scope adoption grows
See why Fujifilm’s new endoscopy warehouse could strengthen service capacity, device uptime and U.S. hospital growth. Read the full analysis.